UA66758C2 - Pharmaceutical formulations comprising growth hormone, method for its production and method for treatment - Google Patents

Pharmaceutical formulations comprising growth hormone, method for its production and method for treatment

Info

Publication number
UA66758C2
UA66758C2 UA98105593A UA98105593A UA66758C2 UA 66758 C2 UA66758 C2 UA 66758C2 UA 98105593 A UA98105593 A UA 98105593A UA 98105593 A UA98105593 A UA 98105593A UA 66758 C2 UA66758 C2 UA 66758C2
Authority
UA
Ukraine
Prior art keywords
growth hormone
pharmaceutical formulations
treatment
production
amino acid
Prior art date
Application number
UA98105593A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of UA66758C2 publication Critical patent/UA66758C2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
UA98105593A 1996-04-24 1997-04-24 Pharmaceutical formulations comprising growth hormone, method for its production and method for treatment UA66758C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK49096 1996-04-24
PCT/DK1997/000184 WO1997039768A1 (en) 1996-04-24 1997-04-24 A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent

Publications (1)

Publication Number Publication Date
UA66758C2 true UA66758C2 (en) 2004-06-15

Family

ID=8094154

Family Applications (1)

Application Number Title Priority Date Filing Date
UA98105593A UA66758C2 (en) 1996-04-24 1997-04-24 Pharmaceutical formulations comprising growth hormone, method for its production and method for treatment

Country Status (20)

Country Link
US (1) US20020077461A1 (de)
EP (2) EP0904099B1 (de)
JP (2) JP4176834B2 (de)
KR (1) KR20000010630A (de)
CN (1) CN1130223C (de)
AT (1) ATE309819T1 (de)
AU (1) AU733592B2 (de)
BR (1) BR9708858A (de)
CA (1) CA2252535C (de)
CZ (1) CZ298292B6 (de)
DE (1) DE69734653T2 (de)
DK (1) DK0904099T3 (de)
ES (1) ES2253774T3 (de)
HU (1) HU229868B1 (de)
IL (2) IL126463A0 (de)
NO (1) NO323360B1 (de)
PL (1) PL188222B1 (de)
RU (1) RU2236250C2 (de)
UA (1) UA66758C2 (de)
WO (1) WO1997039768A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
BR9710536A (pt) 1996-07-24 1999-08-17 Warner Lambert Co Isobutilgaba e seus derivados para o tratamento da dor
AU1302499A (en) * 1997-11-12 1999-05-31 Alza Corporation Buffered drug formulations for transdermal electrotransport delivery
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
JP2004515467A (ja) 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
EP1603588A2 (de) * 2003-03-18 2005-12-14 Ares Trading S.A. Stabilisierung von wachstumshormonen in lösung
CN102813967A (zh) 2003-03-24 2012-12-12 普拉罗美德公司 利用逆向热敏聚合物的暂时栓塞
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US7700086B2 (en) * 2003-11-06 2010-04-20 Pluromed, Inc. Internal clamp for surgical procedures
ES2383691T3 (es) * 2003-12-23 2012-06-25 Pharmacia Corporation Formulación líquida estable de hormonas de crecimiento
UA89781C2 (uk) * 2004-04-07 2010-03-10 Арес Трейдінг С.А. Рідкий склад гормона росту
MX2007007580A (es) * 2004-12-22 2007-12-11 Ambrx Inc Hormona del crecimiento humana modificada.
WO2006071840A2 (en) * 2004-12-22 2006-07-06 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
CN101374536B (zh) * 2004-12-22 2013-09-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
AU2006286486A1 (en) 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
WO2007033427A1 (en) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
EP2049148B1 (de) * 2006-07-06 2016-09-28 Daewoong Co., Ltd. Stabile flüssige formulierung von humanem wachstumshormon
CN101495155A (zh) 2006-07-07 2009-07-29 诺沃-诺迪斯克保健股份有限公司 新的蛋白结合物及其制备方法
AU2007333959A1 (en) * 2006-12-18 2008-06-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
MX338357B (es) 2010-01-22 2016-04-13 Novo Nordisk Healthcare Ag Compuestos estables de la hormona de crecimiento.
CN103002918B (zh) 2010-01-22 2016-05-04 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
ES2566781T3 (es) * 2010-09-21 2016-04-15 Ferring B.V. Procedimiento mejorado para la producción de hormona del crecimiento humana recombinante
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
CA2925416A1 (en) 2013-09-27 2015-04-02 Hanmi Pharm. Co., Ltd. Sustained type human growth hormone preparation
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
KR102655498B1 (ko) 2017-09-07 2024-04-11 제이씨알 파마 가부시키가이샤 수성 의약 조성물
TWI832871B (zh) 2018-06-29 2024-02-21 美商英塞特公司 Axl/mer 抑制劑之調配物
CN115634284A (zh) * 2022-10-31 2023-01-24 景泽生物医药(合肥)有限公司 一种促性腺激素冻干制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
ES2291264T3 (es) * 1991-12-20 2008-03-01 Novo Nordisk A/S Formulacion farmaceutica estabilizada comprendiendo una hormona de crecimiento e histidina.
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
CA2489978A1 (en) * 1992-07-31 1994-02-17 Genentech, Inc. Human growth hormone aqueous formulation

Also Published As

Publication number Publication date
EP0904099A1 (de) 1999-03-31
BR9708858A (pt) 1999-08-03
CA2252535A1 (en) 1997-10-30
DE69734653T2 (de) 2006-08-10
CN1130223C (zh) 2003-12-10
EP0904099B1 (de) 2005-11-16
CZ320798A3 (cs) 1999-03-17
NO984951D0 (no) 1998-10-23
JP2000508665A (ja) 2000-07-11
RU2236250C2 (ru) 2004-09-20
ATE309819T1 (de) 2005-12-15
JP2008231124A (ja) 2008-10-02
IL126463A0 (en) 1999-08-17
NO984951L (no) 1998-10-23
JP4176834B2 (ja) 2008-11-05
AU2634397A (en) 1997-11-12
IL126463A (en) 2007-06-17
KR20000010630A (ko) 2000-02-25
CA2252535C (en) 2009-06-23
CN1216472A (zh) 1999-05-12
NO323360B1 (no) 2007-04-10
DK0904099T3 (da) 2006-03-06
DE69734653D1 (de) 2005-12-22
ES2253774T3 (es) 2006-06-01
HUP9902476A3 (en) 2000-12-28
PL188222B1 (pl) 2004-12-31
HUP9902476A2 (hu) 2000-11-28
HU229868B1 (en) 2014-10-28
PL329386A1 (en) 1999-03-29
WO1997039768A1 (en) 1997-10-30
US20020077461A1 (en) 2002-06-20
AU733592B2 (en) 2001-05-17
EP1629832A1 (de) 2006-03-01
CZ298292B6 (cs) 2007-08-15

Similar Documents

Publication Publication Date Title
UA66758C2 (en) Pharmaceutical formulations comprising growth hormone, method for its production and method for treatment
MD1699F2 (ro) Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei
WO1999012561A3 (en) FRACTURE HEALING USING PTHrP ANALOGS
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
WO2002048183A3 (en) Compositions of peptide crystals
AU2002223684A1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
EP1033998A4 (de) Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer
WO2002043750A8 (en) Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
DE60000288D1 (de) Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten
WO2003047500A3 (en) Vaccine and method for treatment of motor neurone diseases
WO2003028623A3 (en) Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucuous membranes
EE9900428A (et) Köhavastased ravimkoostised
CA2303395A1 (en) Treatment of obesity
SE9801495D0 (sv) Protein formulationa
HUP0003840A2 (hu) Szabályozott hatóanyagleadású gyógyászati készítmények
WO2002051379A3 (en) Thixotropic nasal spray
GB2328872B (en) Method for preparing pharmaceutical formulations
IL145722A0 (en) Pharmaceutical composition comprising growth hormone and interferon
CA2429793A1 (en) Interferon therapeutic effect enhancer
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
NZ333656A (en) Liquid formulation comprising less 5% w/w saturated polyglycosylated C8-10 glycerides (capryl caproyl macrogol glycerides) and a non-peptide for oro-mucosal administration
CA2237643A1 (en) Therapeutic agent for acute hepatic failure
PT1448220E (pt) Agente farmacêutico contendo uma substância activa antiflogística e hidrolisado de lactalbumina e respectiva utilização